Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
Status:
Completed
Trial end date:
2017-08-18
Target enrollment:
Participant gender:
Summary
Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose
of this study is to evaluate the safety and efficacy of teduglutide in children up to the age
of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to
receive the study drug or to participate in a standard-of-care arm. All participants who
complete the study may be eligible to receive the study drug in a long-term extension study.